Usana Health Sciences Inc (USNA) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Usana Health Sciences Inc (USNA) stock forecast summary
Our AI ranks Usana Health Sciences Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Usana Health Sciences Inc is a small-cap company with a market capitalization of $287M. It ranks number 8 by market capitalization among the 29 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast. Its Gross Margin of 77.5% is the highest of the 23 peers that report one.
For USNA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 28.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 23.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, USNA included.
Follow USNA freeUSNA price chart and AI forecast
How USNA ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Usana Health Sciences Inc (USNA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | USNA | Rank |
|---|---|---|
| Market Cap | $287M | 8/29 |
| P/B Ratio | 0.55x | 10/13 |
| EPS | $-1.10 | – |
| Book Value/Share | $28.49 | – |
| Revenue/Share | $49.43 | – |
| FCF/Share | $0.86 | – |
Profitability & Margins
| Metric | USNA | Rank |
|---|---|---|
| ROE | -4.2% | 4/16 |
| ROA | -3.1% | 5/25 |
| ROIC | -0.2% | 8/21 |
| Gross Margin | 77.5% | 1/23 |
| Operating Margin | -0.1% | 6/24 |
| Net Margin | -2.4% | 5/22 |
| EBT Margin | 0.3% | 7/25 |
| Tax Rate | 1253.3% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | USNA | Rank |
|---|---|---|
| Current Ratio | 2.66x | 8/29 |
| Quick Ratio | 1.84x | 8/26 |
| D/E Ratio | 0.25x | 14/17 |
| Financial Leverage | 1.34x | 13/17 |
| Interest Coverage | -86.6x | 22/22 |
| Working Capital | $175M | 8/29 |
Cash Flow
| Metric | USNA | Rank |
|---|---|---|
| Operating Cash Flow | $28M | 4/30 |
| Free Cash Flow | $16M | 4/12 |
| Capital Spending | -$12M | 8/12 |
| OCF Growth YoY | -57.5% | 6/11 |
| FCF Growth YoY | -75.7% | 5/6 |
| FCF/Sales | 1.7% | 7/12 |
| CapEx/Sales | 1.3% | 8/12 |
Operational Efficiency
| Metric | USNA | Rank |
|---|---|---|
| Asset Turnover | 1.30x | 4/17 |
| Receivables Turnover | 273.7x | 2/16 |
| Inventory Turnover | 2.4x | 14/21 |
| Fixed Assets Turnover | 9.7x | 7/17 |
| Days Sales Outstanding | 1 days | 15/16 |
| Days Inventory | 153 days | 7/20 |
| Payables Period | 27 days | 17/18 |
| Cash Conversion Cycle | 127 days | 4/12 |
Income Statement
| Metric | USNA | Rank |
|---|---|---|
| Total Revenue | $913M | 4/18 |
| Operating Income | -$1M | 11/28 |
| Net Income | -$22M | 17/25 |
| SG&A Expense | $335M | 2/16 |
| Cost of Goods Sold | $206M | 4/24 |
Dividend & Shareholder Information
| Metric | USNA | Rank |
|---|---|---|
| Shares Outstanding | 18M | – |
| Net Income Growth | -155.0% | 5/5 |
| EPS Growth | -244.7% | 7/7 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $281M | 40.0% of assets |
| Cash & Short-term Investments | $169M | 24.0% of assets |
| Accounts Receivable | $3M | 0.5% of assets |
| Inventory | $86M | 12.3% of assets |
| Total Liabilities | $132M | 18.8% of assets |
| Short-term Debt | $90M | 12.8% of assets |
USNA quarterly financials and insider trading
Usana Health Sciences Inc (USNA) industry peers
Companies classified under the same SEC industry code as Usana Health Sciences Inc (Medicinal Chemicals & Botanical Products): 33 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| USNA Usana Health Sciences Inc | ▼ | $287M |
| DFTX Definium Therapeutics, Inc. | ▲ | $4.31B |
| TRLV Trulieve Cannabis Corp. | ▶ | $1.93B |
| CRON Cronos Group Inc. | ▶ | $1.18B |
| TLRY Tilray Brands, Inc. | ▶ | $414M |
| SNDL Sndl Inc. | ▶ | $322M |
| CGC Canopy Growth Corp | ▶ | $302M |
| GLAS Glass House Brands Inc. | ▼ | $301M |
| ACB Aurora Cannabis Inc | ▶ | $253M |
| NAGE Niagen Bioscience, Inc. | ▶ | $197M |
| MDWD Mediwound Ltd. | ▶ | $152M |
| AAWH Ascend Wellness Holdings, Inc. | ▲ | $80M |
| FTLF Fitlife Brands, Inc. | ▶ | $79M |
| BTMD Biote Corp. | ▲ | $35M |
| RAPH Raphael Pharmaceutical Inc. | ▼ | $30M |
| CHUC Charlie's Holdings, Inc. | ▶ | $27M |
| MRMD Marimed Inc. | ▲ | $24M |
| CFOO China Foods Holdings Ltd. | ▼ | $21M |
| MTEX Mannatech Inc | ▲ | $14M |
| ADIA Adia Med, Inc. | ▲ | $13M |
| GLUC Glucose Health, Inc. | ▼ | $9M |
| NAII Natural Alternatives International Inc | ▲ | $7M |
| BON Bon Natural Life Ltd | ▼ | $7M |
| PLSH Panacea Life Sciences Holdings, Inc. | ▲ | $6M |
| CYAN Cyanotech Corp | ▲ | $5M |
| IMCC Im Cannabis Corp. | ▼ | $2M |
| AIBT Aibotics, Inc. | ▼ | $2M |
| NPHC Nutra Pharma Corp | ▼ | $720K |
| MEHA Functional Brands Inc. | ▼ | $290K |
| CBDY Target Group Inc. | ▼ | N/A |
| HYEX Healthy Extracts Inc. | ▲ | N/A |
| NTRR Neutra Corp. | ▼ | N/A |
| SNYRQ Synergy Chc Corp. | ▼ | N/A |
Where USNA sits on the market map
Usana Health Sciences Inc (USNA) stock news
Loading...
Usana Health Sciences Inc (USNA) stock forecast FAQ
What is the Usana Health Sciences Inc (USNA) stock forecast?
Our AI ranks Usana Health Sciences Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Usana Health Sciences Inc stock predictions?
For USNA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 28.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 23.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Usana Health Sciences Inc forecasts updated?
Usana Health Sciences Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Usana Health Sciences Inc's industry peers?
33 issuers in our coverage, USNA included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Canopy Growth Corp (CGC).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.